Clinical Trials | 10397, Optimizing Antibody-Drug Conjugate Therapy through Molecular Analysis for Therapy Choice (ADC MATCH)

The University of Virginia is conducting a clinical research study for adults ages 18 and over who have cancer that has become worse following treatment with all available therapies known to be beneficial for your disease, you are not able to tolerate the standard therapy for your cancer, no standard therapy exists for your cancer, or you are willing to forego standard therapies known to be beneficial for your cancer. This study consists of a screening study, and the screening steps will determine whether you are eligible to participate in an ADC treatment substudy. Each available substudy will test a different targeted treatment called an Antibody-Drug Conjugate (ADC). ADCs are antibodies that target proteins on cancer cells and are linked to chemotherapy. Thus, ADCs target chemotherapy to cancer cells. If you decide to participate in this research study, you will have a sample of your tumor tissue tested to see whether it has an ADC target that matches a specific substudy. If the RNA and protein testing results show that your tumor has an ADC target that matches a specific available substudy, you will be asked to participate in that substudy. If you have a match to a substudy, you will talk to your study doctor to decide if you are able to participate in the substudy. If you decide to participate in one of the available substudies, you will take the ADC treatment that is being tested until your cancer becomes worse, or you have side effects and can no longer tolerate the ADC treatment. Additional details regarding the substudies will be provided to you by the study doctor. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. Additional information can be found here: https://clinicaltrials.gov/study/NCT06311214 [email protected]